Variant · Expression
KDR Overexpression
CI-VAR-00003178Explore in graph →CIViC 2204
Curated evidence
Evidence by cancer (2 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 25639617
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Breast Angiosarcoma1 | ||||||||
| KDR Overexpression | Sunitinib | Predictive | C | Supports Sensitivity Response | 3 | submitted | EID5910gene expression assay performed earlier demonstrated a This case report of a patient with refractory breast angiosarcoma shows a potential therapeutic benefit of sunitinib due to the upregulation of V… (full text at CIViC) PMID 25639617 · Silva et al., 2015 · Open in CIViC | civic |
| Neuroendocrine Tumor1 | ||||||||
| KDR Overexpression | Pazopanib | Predictive | B | Supports Sensitivity Response | 3 | submitted | EID7854Phase 2 study of pazopanib in pretreated advanced neuroendocrine tumors. Study found that patients with immunoexpression of VEGFR2 (KDR) above the median had longer PFS (12.6 months vs 9.1 months, P=… (full text at CIViC) PMID 26063633 · | |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available